|
|
|
|
Kyverna Therapeutics Inc (NASDAQ: KYTX) |
|
Price: $2.8100
$-0.02 
-0.531%
|
| Day's High:
| $2.97
| Week Perf:
| -14.33 %
|
| Day's Low: |
$ 2.76 |
30 Day Perf: |
10.2 % |
| Volume (M): |
538 |
52 Wk High: |
$ 5.70 |
| Volume (M$): |
$ 1,512 |
52 Wk Avg: |
$3.24 |
| Open: |
$2.87 |
52 Wk Low: |
$1.79 |
|
|
| Market Capitalization (Millions $) |
121 |
| Shares
Outstanding (Millions) |
43 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-145 |
| Cash Flow (TTM) (Millions $) |
-167 |
| Capital Exp. (TTM) (Millions $) |
2 |
Kyverna Therapeutics Inc
Company Address: 5980 Horton St. Emeryville 94608 CA
Company Phone Number: 925-2492 Stock Exchange / Ticker: NASDAQ KYTX
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Announcement
Published Fri, Jan 31 2025 10:23 PM UTC
In an urgent alert, the Rosen Law Firm, a highly recognized entity in the field of investor rights, has prompted investors of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) to secure legal counsel ahead of a critical February 7, 2025 deadline concerning a securities class action. This action pertains to investors who acquired common shares during the company?s initial public offe...
|
| Announcement
Published Mon, Dec 30 2024 6:25 PM UTC
In a significant development for stakeholders of Kyverna Therapeutics, Inc. investors are being alerted to an impending class action lawsuit against the company. Levi & Korsinsky, LLP, a prominent securities litigation firm, has issued a notice to investors regarding the class action lawsuit, urging them to be aware of a critical deadline. The legal proceedings come with a l...
|
| Announcement
Published Mon, Dec 30 2024 8:30 AM UTC
In a recent development significant to investors in the biotechnology sector, Rosen Law Firm, a prominent global investor rights law firm, has issued a reminder to those who purchased common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX). The firm emphasizes that these investors, whose stock purchases are pursuant and/or traceable to the company?s initial public offering...
|
| Announcement
Published Thu, Dec 26 2024 8:10 PM UTC
Rosen Law Firm Urges Kyverna Therapeutics Investors to Take Legal Action by February Deadline In the turbulent world of biotechnology finance, investor confidence is a precious commodity. The case of Kyverna Therapeutics, Inc. (NASDAQ: KYTX), a rising star in the biopharmaceutical industry, epitomizes the complex interplay between corporate ambition and investor rights. Rose...
|
| Announcement
Published Sat, Dec 21 2024 12:32 AM UTC
In the evolving landscape of biotech investments, the recent announcement from Rosen Law Firm regarding Kyverna Therapeutics, Inc. (NASDAQ: KYTX) has highlighted a significant potential legal battle stemming from the company s initial public offering (IPO). Investors and stakeholders should be aware of the implications of this development, particularly with the looming dead...
|
| Per Share |
Current |
| Earnings (TTM) |
-3.28 $ |
| Revenues (TTM) |
-
|
| Cash Flow (TTM) |
- |
| Cash |
5.61 $
|
| Book Value |
5.18 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-3.28 $
|
| Revenues (TTM) |
- |
| Cash Flow (TTM) |
- |
| Cash |
5.61 $
|
| Book Value |
5.18 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
17.51%